Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Milberg LLP Announces Investigation of Board of Directors' Decision to Sell Xura, Inc. to Siris Capital Group, LLC

PR Newswire May 24, 2016

Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Canada NewsWire May 24, 2016

The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium

Canada NewsWire April 18, 2016

Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman

Canada NewsWire April 4, 2016

Resverlogix Announces Corporate Update Webcast

Canada NewsWire March 1, 2016

Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal

Canada NewsWire January 25, 2016

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE

Canada NewsWire November 11, 2015

Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference

Canada NewsWire November 9, 2015

Stonegate Capital Partners Initiates Coverage on Resverlogix Corp.

Accesswire November 5, 2015

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

Canada NewsWire October 26, 2015

Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum

Canada NewsWire October 22, 2015

Resverlogix Announces Voting Results

Canada NewsWire September 30, 2015

Resverlogix Provides Research and Development Update in New York City

PR Newswire September 29, 2015

Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases

PR Newswire September 24, 2015

Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference

PR Newswire September 10, 2015

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor

Canada NewsWire August 31, 2015

Resverlogix CEO Donald McCaffrey Interviewed by The Life Sciences Report

Marketwired August 27, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015